Post #3 put the caveat in the right place and I want to underline it. Publication patterns in the BPC-157 literature: a large proportion of the evidence comes from one research group. That is not necessarily wrong — one group can do excellent work — but it is worth noting when evaluating the breadth of support for a…
Why the absence of controlled human data on BPC-157 matters more than people admit — that is the question, and I have not found it answered plainly anywhere I have looked.
I would like to know what people here actually do about absence of controlled human data, as distinct from what is usually recommended. Those have diverged in every other subject I have looked at closely.
Mine is below, with the reasoning, including the parts I am not confident about.
Agreed, and I will stop repeating the version of this I had been repeating.
The useful distinction on absence of controlled human data is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars.
Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no excuse for an unverified identity on this compound.
The claim is narrower than it sounds, and deliberately so.
Post #3 put the caveat in the right place and I want to underline it.
Publication patterns in the BPC-157 literature: a large proportion of the evidence comes from one research group. That is not necessarily wrong — one group can do excellent work — but it is worth noting when evaluating the breadth of support for a claim.
Adding it because I spent an afternoon working it out and nobody should have to twice.
Narrowing post #4, because the general version has more than one answer.
Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity finding but it does say something about how the vial was made and how it travelled.
None of the above is medical advice and I am not qualified to give any.
Reading back through the absence of controlled human data threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.
Thank you for taking the time. That was more work than a reply usually is.
Answering the question post #9 raises rather than the one it answers.
Anecdote is the whole of the human evidence base here, and this community's convention is to say so rather than to aggregate anecdotes into something that sounds like data.
This is the sort of thing that ought to be settled and apparently is not.
The arithmetic in post #13 is right; the assumption feeding it is the part to check.
BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.
It cost nothing to check and would have cost something not to.
Where I part company with post #13, and it is a narrow parting.
Marking my uncertainty on absence of controlled human data explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past the case in the first post.
Taking absence of controlled human data seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences.
Mechanistic accounts in this area run well ahead of the outcome data. Angiogenesis and cell migration effects in a dish are real observations and are a long way from a clinical result.
Adding the measurement that post #17 says would settle it.
The absence of human trials means there is no established dose, no established interval and no established duration. Protocols circulating in this space are convention rather than evidence and should be described as such.
Happy to be corrected if someone holds better data than mine.
This follows post #17 rather than contradicting it.
What would change the position on repair peptides: adequately powered, published, peer-reviewed randomised controlled human trials with pre-specified outcomes. That is the standard applied to every other therapeutic claim on this site and it is the standard applied here.
The mechanism is plausible, which is not the same as established.
Research use only, not approved for human use, and in this family that statement carries more weight than usual because the published human safety data is effectively absent rather than merely limited.
The number is defensible. The precision I gave it is not.
Narrowing post #21, because the general version has more than one answer.
Two questions I would want answered before drawing anything from the absence of controlled human data data above: how were the cases selected, and what happened to the ones that dropped out.
Everything in post #20 holds. The case it does not cover is the one I have.
Stability in solution is the practical constraint. Dry, these keep well; reconstituted, the supplier's own data usually covers a shorter period than people assume.
For anyone arriving from search engines: this subcategory discusses published preclinical work and the absence of published clinical work. It does not endorse or recommend these compounds.
I am confident about the direction and much less about the magnitude.
The distinction between "no evidence it works" and "evidence it does not work": we have the first for these compounds. That is genuinely different from the second and the distinction matters, but it also means treatment plans based on these compounds are being built on theoretical grounds, not empirical ones.
The disagreement above is smaller than it looks once the terms are fixed.
Answering the question post #24 raises rather than the one it answers.
The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.
That distinction has done more work for me than anything else in this category.
Post #26 is the version of this I will quote in future. One addition.
The version of absence of controlled human data that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.